Proteintech Germany triples its space with a new office and laboratory
20.3.2024 21:57:00 EET | Business Wire | Press release
Proteintech, the benchmark in antibodies and life science solutions, announces that its branch in Martinsried near Munich has moved into its new laboratory and office space. The new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320643097/en/
Proteintech celebrates the opening with a ribbon cutting event. Pictured: Dr. Jason Li, CEO of Proteintech, along with Proteintech executives and local government officials. (Photo: Business Wire)
In 2020, the Proteintech Group acquired ChromoTek GmbH, which specializes in the development and production of Nanobody-based reagents and was located at the incubator IZB. The gradual integration of Chromotek into the parent company, Proteintech Group, enabled new sales markets and channels for the products manufactured in Martinsried. The Martinsried site also serves as a central logistics hub for all Proteintech products for customers in the European Union.
Rainer Gebhart, Site Manager at Proteintech Germany, said: “Here we offer state-of-the-art working environments for daily top performance and innovation of our employees - our most important capital for a continued successful future.” He also explained, “The move supports our customer focused strategy. With a larger team in Martinsried – and in cooperation with our sister site in Manchester, UK – we can better serve our customers in Europe and further gain market share.”
Dr Jason Li, CEO of Proteintech said, “There is a great future for Nanobody technology and we’re excited to be at the forefront of this.” He also stated, “Proteintech has R&D and production laboratories on three continents in its major sites (Chicago, Wuhan and Martinsried). All three sites have seen expansion in the past year and the collaboration between them means we can bring new and innovative products to the market.”
About Proteintech Group
Proteintech Group Inc., founded in 2001, is a leading manufacturer of antibodies, proteins, nanobodies, and immunoassays. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. Proteintech offers antibodies, proteins and immunoassays across research areas with over 200,000 products cited. In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. Proteintech sites are ISO13485 and ISO9001 accredited.
To learn more about Proteintech, please visit www.ptglab.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320643097/en/
Contact information
Katie Bellows
katie@ptglab.com
ph. +1-312-455-8498
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Introduces Platform for Stablecoin Minting, Movement and Management16.7.2026 17:30:00 EEST | Press release
Today, Visa (NYSE: V) announced the Visa Stablecoin Platform (VSP), a new enterprise platform designed to help financial institutions, fintechs, and crypto natives access stablecoin capabilities through a single Visa-managed environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716292689/en/ Building on Visa’s broader crypto strategy, VSP gives FIs, fintechs and other payment providers a simple way to access, store, and redeem stablecoins, beginning with Open USD (OUSD), a new stablecoin recently introduced by Open Standard. This includes onchain wallet infrastructure through a newly introduced Wallet-as-a-Service offering and connectivity for minting and burning Open USD. “Stablecoins are opening up a new layer of programmable money, but for most institutions the hard part isn’t the concept, it’s the operational reality,” said Jack Forestell, Chief Product and Strategy Officer, Visa. “With the Visa Stablecoin Platf
Andersen Consulting Adds Collaborating Firm Smartbridge16.7.2026 16:30:00 EEST | Press release
Andersen Consulting announces a Collaboration Agreement with Smartbridge, a Texas-based digital and AI technology firm, enhancing its capabilities in data and analytics, and digital transformation services. Founded in 2003, Smartbridge helps organizations accelerate their digital transformation and modernize operations through digital innovation, AI, data and analytics, and application modernization services. The firm works with clients in the oil and gas, medtech, and restaurant industries, combining advisory and technology services to enable enterprise transformation and growth. Leveraging strategic relationships with leading technology providers, Smartbridge helps organizations connect data, improve decision-making, and accelerate business outcomes. “Organizations today are looking to accelerate their digital and AI transformation and are searching for practical ways to translate innovation into measurable business value,” said Sri Raju, CEO of Smartbridge. “Our team focuses on help
Cyclic Materials Appoints Tomasz Poznar as Chief Commercial Officer to Accelerate Global Commercial Growth16.7.2026 16:20:00 EEST | Press release
Cyclic Materials, the rare earth recycling company building a circular supply chain for rare earth elements and critical materials, today announced the appointment of Tomasz Poznar, Ph.D., as Chief Commercial Officer. The appointment strengthens Cyclic Materials’ executive team as the company accelerates commercial expansion across North America, Europe, and Asia. Most recently, Poznar served as Chief Commercial Officer at Ascend Elements, where he led the company’s global commercial strategy, strategic partnerships, and business development. During his tenure, he helped secure more than USD $1.5 billion in commercial agreements, including a landmark USD $1 billion supply agreement with a major global automaker, while also supporting approximately USD $320 million in TCTF government funding that accelerated the company’s growth in North America and Europe. Prior to Ascend Elements, Poznar held leadership and engineering positions at A123 Systems, EnerDel, Delco Remy, and Volvo, where h
Modon Holding and Nammos Hotels & Resorts Bring Nammos Ras El Hekma to Egypt’s North Coast16.7.2026 15:50:00 EEST | Press release
Abu Dhabi-based Modon Holding and Nammos Hotels & Resorts have announced Nammos Ras El Hekma – the renowned lifestyle and hospitality brand’s first fully integrated destination in Egypt. Located within the Wadi Yemm precinct, the development will bring Ras El Hekma’s promise of timeless Mediterranean living to life, combining Nammos Residences, Nammos Resort, Nammos Village, and a curated selection of all-day dining and wellness experiences, including the globally renowned Nammos Restaurant & Beach Club. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716740934/en/ Modon Holding and Nammos Hotels & Resorts bring Nammos Ras El Hekma to Egypt’s North Coast (Photo: AETOSWire) Nammos Ras El Hekma represents a new expression of contemporary Mediterranean luxury. Reflecting both the natural beauty of Egypt’s North Coast and the refined yet vibrant lifestyle associated with Nammos, the destination introduces a lifestyle concept i
Crown Bioscience Joins C-Path's NAMs Developer Coalition to Advance Human-Relevant Models in Drug Development16.7.2026 15:30:00 EEST | Press release
Crown Bioscience is a global contract research organization (CRO) specializing in oncology drug discovery and development, today announced it has joined Critical Path Institute's (C-Path) New Approach Methodologies Developer Coalition (NAMs-DC), a collaborative initiative dedicated to advancing the validation, qualification and regulatory adoption of innovative human-relevant research methods. Crown Bioscience joins a growing community of technology developers, pharmaceutical companies, regulatory stakeholders and scientific experts working to accelerate the adoption of New Approach Methodologies (NAMs) across drug discovery and development. Through its participation in NAMs-DC, Crown Bioscience will contribute expertise spanning patient-derived xenograft (PDX) models, patient-derived tumor organoids, ex vivo patient tissue platforms, translational biomarker analysis and bioinformatics. The company is also expanding its capabilities across organoid-based toxicology, organ-on-chip colla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
